No recurrence (n=20) | Recurrence (n=29) | P value | |
Sex | |||
Female | 9 (45.0%) | 9 (31.0%) | 0.995 |
Male | 11 (55.0%) | 20 (69.0%) | |
Age | |||
Mean (SD) | 73.4 (12.1) | 68.4 (7.91) | 0.632 |
Median (min, max) | 75.0 (50.0, 89.0) | 69.0 (54.0, 83.0) | |
Grade 2 | |||
High | 5 (25.0%) | 10 (34.5%) | NA |
Low/intermediate | 15 (75.0%) | 19 (65.5%) | |
P value | 0 (0%) | 0 (0%) | |
T cell infiltrates | |||
High | 7 (35.0%) | 4 (13.8%) | 0.13 |
Low | 2 (10.0%) | 8 (27.6%) | |
Moderate | 11 (55.0%) | 17 (58.6%) | |
Clonality | |||
High | 9 (45.0%) | 12 (41.4%) | 0.194 |
Moderate/low | 11 (55.0%) | 17 (58.6%) | |
T cells total | |||
Mean (SD) | 0.165 (0.146) | 0.170 (0.134) | 0.289 |
Median (min, max) | 0.105 (0.0100, 0.620) | 0.140 (0.0200, 0.670) | |
Overall survival | |||
Mean (SD) | 4.68 (4.60) | 3.34 (3.18) | 0.98 |
Median (min, max) | 2.60 (0.300, 17.4) | 2.00 (0.400, 13.8) | |
Total immune content | |||
Mean (SD) | 0.365 (0.225) | 0.372 (0.218) | 0.678 |
Median (min, max) | 0.305 (0.100, 0.960) | 0.320 (0.0700, 0.900) |
A t-test was used for continuous data, and a χ2 test was used for categorical data to analyze clinical characteristics and immunosequencing data in relation to RFS at 3 years.
RFS, recurrence-free survival.